## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.15 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($701.00)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery**
- Source: BioSpace | 20251210T050857 | Bullish | Relevance: 99%
-  After a challenging year marked by regulatory rejections and manufacturing issues that saw its shares drop to a four-year low of $483, Regeneron has rebounded significantly. The company's stock has climbed back to $787, exceeding its January 1st price of $715 and showing a 10% increase for the year, driven by renewed analyst optimism and recent critical approvals for its Eylea drug. Looking ahead, Regeneron is poised for further growth, particularly with the continued success of Dupixent and potential reduced regulatory burdens for its pipeline assets under new FDA guidelines.

**2. State Street Corp Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251210T115453 | Bullish | Relevance: 99%
-  State Street Corp increased its stake in Regeneron Pharmaceuticals, Inc. by 0.9% in the second quarter, now holding 4,832,002 shares valued at approximately $2.54 billion. Analysts generally have a positive outlook on REGN, with an average rating of "Moderate Buy" and a price target of $777.36. Regeneron recently surpassed earnings and revenue estimates and pays a quarterly dividend.

**3. RBC Capital reiterates Sector Perform rating on Regeneron stock**
- Source: Investing.com | 20251209T150836 | Somewhat-Bullish | Relevance: 99%
-  RBC Capital has reaffirmed its Sector Perform rating and $708.00 price target for Regeneron Pharmaceuticals (NASDAQ:REGN), noting recent stock appreciation due to positive developments like EyleaHD label expansion and Dupixent's continued strength. However, the firm expresses uncertainty about the differentiation of Regeneron's fianlimab against Bristol Myers Squibb's Opdualag, which could temper future stock upside. Despite this, other analysts have set higher price targets for Regeneron, reflecting varying outlooks on its pipeline and collaborations.

**4. Regeneron (REGN): Revisiting Valuation After a Short-Term Pullback and Longer-Term Shareholder Weakness**
- Source: Simply Wall Street | 20251210T020920 | Somewhat-Bullish | Relevance: 99%
-  Regeneron Pharmaceuticals (REGN) has experienced a short-term pullback following a strong quarter, leading investors to re-evaluate its valuation. Despite a recent dip, the stock maintains an impressive 90-day return, though its one-year total shareholder return is negative. Analysts suggest the stock is undervalued, with potential upside driven by EYLEA HD's adoption and anticipated regulatory approvals, but warn of risks from sustained EYLEA pressure and trial stumbles.

**5. iSAM Funds UK Ltd Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251210T120914 | Somewhat-Bullish | Relevance: 99%
- iSAM Funds UK Ltd has acquired 2,539 new shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) valued at approximately $1,333,000, as disclosed in its recent 13F filing. Other hedge funds have also adjusted their holdings in the biopharmaceutical company, reflecting ongoing institutional interest. The company recently reported strong earnings, exceeding analyst estimates, and has a consensus "Moderate Buy" rating from analysts with an average price target of $777.36.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |
| 2025-12-03 | Morgan Stanley | $767 | $767 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Morgan Stanley | down | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($1.41M) |
| Sells | 12 ($16.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $17M sold (12 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +16%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.15 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (5 raises, avg +16%). Insider selling cluster ($16.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $79.2B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.15 |
| Forward P/E | 19.5 |
| Current P/E | 17.3 |
| YoY Growth | -11.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -2.9% to -0.2% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (4.1%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-7.23), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.25% (CS: 44) | Neutral |
| RSI_14 | 60.6 | Neutral |
| MACD Histogram | -7.23 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.135x | Above |
| vs SMA200 | 1.247x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $746.80
- **Stop Loss:** $701.00 (6.1% risk)
- **Target:** $838.40 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 30
- **Position Value:** $22,404.00
- **Portfolio %:** 22.40%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*